EGFRvIII

EGFRvIII

EGFRvIII Overview

Molecule Name
Epidermal growth factor receptor variant III
Drug Development Progress
Drugs in Clinical Trials14
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
Background
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.

EGFRvIII Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
WSD-0922WSD0922; WSD-0922Phase 2 ClinicalWayshine Biopharm International Ltd
Astrocytoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma
Details
Anti-EGFRvIII-CAREGFRvIII CAR; Anti-EGFRvIII-CARPhase 2 ClinicalKite Pharma, National Cancer Institute
Brain Neoplasms; Glioblastoma; Glioma; Gliosarcoma
Details
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian)CPGJ-602; 602; CPGJ602; CPGJ 602Phase 2 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Colorectal Neoplasms
Details
WSD-0922-FUWSD0922-FU; WSD-0922-FUPhase 2 ClinicalWayshine Biopharm International Ltd
Astrocytoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Lung Neoplasms; Neoplasms; Solid tumours
Details
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania)LXF-821Phase 1 ClinicalNovartis Pharma Ag, University Of Pennsylvania
Glioblastoma
Details
EGFRvIII-CARPhase 1 ClinicalDuke University Medical Center
Glioblastoma
Details
Metabolically Armed EGFRvIII CAR-T cells therapy (Leman Biotech)Meta10-EGFRvIII; LMC005Phase 1 ClinicalLeman Biotech Co Ltd
Glioblastoma
Details
APTN-101CBRX-101; APTN 101Phase 1 ClinicalAdaptin Bio Inc
Glioblastoma; Glioma
Details
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine)Phase 1 ClinicalCalifornia Institute For Regenerative Medicine, National Cancer Institute
Glioblastoma
Details
Targeted EGFRvIII autochimeric antigen receptor T cell therapy (DCTY)DCTY0801; DCTY-0801Phase 1 ClinicalBeijing DCTY Biotech Co Ltd
Glioblastoma; Glioma
Details
SNC-109SNC109; SNC-109Phase 1 ClinicalShanghai Simnova Biotechnology Co Ltd
Glioblastoma
Details
RO-7428731RO-7428731; RG-6156Phase 1 ClinicalF. Hoffmann-La Roche Ltd
Glioblastoma
Details
GNC-039GNC-039Phase 1 ClinicalSichuan Baili Pharmaceutical Co Ltd
Glioma; Hematologic Neoplasms; Neoplasm Metastasis; Solid tumours
Details
89Zr-ABT806ClinicalHuashan Hospital
Glioma
Details